Retatrutide vs Setmelanotide
The world's first triple-action weight loss peptide that simultaneously activates three hormone receptors—GIP, GLP-1, and glucagon—delivering unprecedented weight loss results of up to 24% body weight in clinical trials [1][2].
Targeted MC4R agonist for rare genetic obesity caused by melanocortin pathway defects
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Quick comparison
Dose range
Retatrutide
4–8 mg
Setmelanotide
3–3 mg
Frequency
Retatrutide
Once weekly
Setmelanotide
Once daily
Administration
Retatrutide
Subcutaneous injection
Setmelanotide
subcutaneous injection
Cycle length
Retatrutide
12+ weeks
Setmelanotide
Ongoing/indefinite
Onset speed
Retatrutide
Moderate (1-2 weeks)
Setmelanotide
Moderate (1-2 weeks)
Evidence level
Retatrutide
Moderate human trials (Phase 1-2)
Setmelanotide
Strong human trials (Phase 3 or FDA approved)
Benefit ratings
Weight Loss Power
Metabolic Health
Appetite Control
Weight Management
Quality of Life
Compound specifications
Retatrutide
Molecular formula
C221H342N46O68
Molecular weight
4731 g/mol
Half-life
~6 days (allows once-weekly dosing)
Bioavailability
High via subcutaneous injection
CAS number
2381089-83-2
Setmelanotide
Molecular formula
C49H68N18O9S2
Molecular weight
1,117.3 Da
Half-life
~11 hours
Bioavailability
~79% subcutaneous bioavailability
CAS number
920014-72-8
Dosing compared
Retatrutide
Subcutaneous
Weeks 1-4
2 mg
Once weekly · Weeks 1-4 (then escalate 2 mg every 4 weeks)
Phase 2 obesity trial initiated higher-dose arms at 2 mg weekly with stepwise 2 mg increases every 4 weeks to limit GI effects [1].
Maintenance after titration
4-8 mg
Once weekly · Maintenance after titration
Mid-range maintenance doses; 8 mg produced ~22% mean weight loss at 48 weeks in the phase 2 trial [1][3].
Maintenance (highest studied)
12 mg
Once weekly · Maintenance (highest studied)
Highest studied dose; produced ~24% mean weight reduction at 48 weeks [1]. Still investigational (not FDA-approved).
Setmelanotide
Subcutaneous
First 2 weeks
2 mg
Once daily · First 2 weeks
FDA Imcivree starting dose for BBS or POMC/PCSK1/LEPR-deficiency obesity in patients 2 years and older; injected on waking [6]. (Acquired hypothalamic obesity starts lower at 0.5 mg daily.)
Ongoing maintenance
3 mg
Once daily · Ongoing maintenance
Recommended maintenance/maximum dose after tolerating 2 mg for 2 weeks; first approval and pivotal trials [1][6]. Effective for MC4R-pathway and hypothalamic obesity [2][3].
Best suited for
Retatrutide
Significant Obesity Management
If you need to lose a substantial amount of weight, retatrutide is showing unprecedented results. Phase 2 trials demonstrated average weight loss of 24% at the highest dose—that's nearly 60 pounds for someone weighing 250 lbs [1]. No other medication has matched this [1].
Type 2 Diabetes with Obesity
Retatrutide tackles both problems at once. It dramatically improves blood sugar control (HbA1c reductions of up to 2%) while delivering major weight loss [6]. The dual benefit makes it especially valuable for diabetics struggling with weight.
Metabolic Syndrome Warriors
If you're dealing with the cluster of issues that includes high blood sugar, excess belly fat, abnormal cholesterol, and high blood pressure, retatrutide's triple mechanism attacks multiple aspects of metabolic dysfunction simultaneously [5].
Fatty Liver Disease (MASLD)
Early research shows retatrutide may significantly reduce liver fat [7]. For people with non-alcoholic fatty liver disease, this peptide offers hope through weight loss plus direct metabolic improvements that benefit liver health.
Setmelanotide
Treating obesity caused by confirmed POMC deficiency mutations
Setmelanotide is particularly well-suited for individuals focused on treating obesity caused by confirmed pomc deficiency mutations. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Managing obesity from PCSK1 or LEPR genetic defects
Setmelanotide is particularly well-suited for individuals focused on managing obesity from pcsk1 or lepr genetic defects. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Reducing hyperphagia and body weight in Bardet-Biedl syndrome
Setmelanotide is particularly well-suited for individuals focused on reducing hyperphagia and body weight in bardet-biedl syndrome. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Addressing early-onset severe obesity with identified melanocortin pathway mutations
Setmelanotide is particularly well-suited for individuals focused on addressing early-onset severe obesity with identified melanocortin pathway mutations. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Side effects
Retatrutide
Common
- Nausea
- Diarrhea
- Constipation
- Decreased appetite
Uncommon
- Increased heart rate
- Injection site reactions
Serious
- Pancreatitis
- Gallbladder problems
Setmelanotide
Common
- Skin Hyperpigmentation
- Injection Site Reactions
- Nausea
- Diarrhea
Uncommon
- Hair Color Darkening and Nevus Changes
Serious
- Depression and Suicidal Ideation
Safety & evidence
Retatrutide
Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Retatrutide has shown a generally favorable safety profile in Phase 1 and Phase 2 clinical trials involving over 600 participants [1][6]. Most side effects are gastrointestinal and tend to improve over time [3]. The medication appears well-tolerated when doses are increased gradually. No major safety signals have emerged, but larger Phase 3 trials are still ongoing [3].
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Pregnancy or planning to become pregnant
- History of severe pancreatitis
- Known allergy to GLP-1 receptor agonists
Setmelanotide
Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Setmelanotide demonstrates favorable tolerability in Phase 3 trials with safety data from over 200 patients across POMC, PCSK1, LEPR-deficient, and Bardet-Biedl syndrome populations. The most common adverse effect is dose-dependent skin hyperpigmentation (>60% of patients) due to off-target MC1R activation on melanocytes—a manageable, reversible pharmacological effect rather than true toxicity. Serious psychiatric adverse events including depression and suicidal ideation require baseline mental health screening and ongoing monitoring in all patients.
Contraindications
- Known hypersensitivity to setmelanotide or any excipients
- Obesity not caused by POMC, PCSK1, LEPR deficiency or Bardet-Biedl syndrome
- Patients without genetic confirmation of melanocortin pathway mutations
- Use during pregnancy (animal studies suggest potential fetal harm)
Which is right for you?
Choose Retatrutide if...
- Significant weight loss
- Type 2 diabetes management
- Metabolic health improvement
- Body composition optimization
Choose Setmelanotide if...
- Treating obesity caused by confirmed POMC deficiency mutations
- Managing obesity from PCSK1 or LEPR genetic defects
- Reducing hyperphagia and body weight in Bardet-Biedl syndrome
- Addressing early-onset severe obesity with identified melanocortin pathway mutations